Fundraising Fox

AMR Action Fund β€” Full Portfolio

19 tracked investments Β· listed companies and verified rows first

BiomXbiomx.comin𝕏NYSE: PHGE

Biotech

Jesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)Jonathan Solomon(Chief Executive Officer)Merav Bassan(Chief Development Officer)Gregory Merril(Director)

Antabioantabio.cominβœ“ verified

Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.

BiotechHealthtech

Centauritherapeuticscentauritherapeutics.cominβœ“ verified

Centauri Therapeutics is an immunotherapy company developing treatments for infectious diseases and oncology using its proprietary Alphamer technology, which redirects naturally existing antibodies against life-threatening diseases.

BiotechHealthtech

Abexxa BiologicsSep 2016SEC filingmedium confidence

BiotechArlington, US

Jon Weidanz(Director and President)Debra Weidanz(CEO and Director)

Board seatMartin HeideckerΒ· per SEC Form D Β· $1.7M raise Β· filed Sep 2016

Adaptive Phage TherapeuticsMay 2023SEC filingmedium confidence

BiotechGaithersburg, US

Evan Loh(Director)Gregory L. Merril(Executive Officer, Director, Promoter)Jana Jensen(Director)Raymond L. Martz(Director)Carl R. Merril(Executive Officer, Director)

BoardJonathan Leff(Director)

Board seatMartin HeideckerΒ· per SEC Form D Β· $30M raise Β· filed Jun 2023

Elion Therapeuticseliontx.comJun 2024

BiotechNew York, US

Jim Flynn(Director)Kieren Marr(Executive Officer, Director)

BoardJonathan Leff(Director)

Board seatMartin HeideckerΒ· per SEC Form D

Rgenta Therapeuticsrgentatx.cominJan 2020SEC filingmedium confidence

Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)

Board seatMartin HeideckerΒ· per SEC Form D Β· $38M raise Β· filed Mar 2021

Vedanta Biosciencesvedantabio.comin𝕏Mar 2023

BiotechHealthtechCambridge, US

Bernat Olle(Executive Officer, Director)Daniel Couto(Executive Officer)Mark Mullikin(Executive Officer)Jeffrey Silber(Executive Officer)Bharatt Chowrira(Director)Christopher Viehbacher(Director)

Board seatMartin HeideckerΒ· per SEC Form D

Venatorx PharmaceuticalsMar 2022

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

Malvern, US

Board seatMartin HeideckerΒ· per SEC Form D

[4]f2g.com
BioVersysbioversys.comin𝕏

BioVersys is a Swiss pharmaceutical company developing small-molecule drugs with novel modes of action to treat drug-resistant bacterial infections, addressing antimicrobial resistance (AMR).

BiotechDeep TechHealthtechBasel, CH

Patternpattern.bioin𝕏

Pattern develops rapid diagnostic testing for bacterial infections using single-cell microbiology to identify pathogens and antibiotic susceptibility in hours rather than days.

BiotechDigital HealthMedical Devices

Pattern Bioscience

Developing a diagnostics platform using single-cell analysis and machine learning to rapidly identify bacterial pathogens and determine antibiotic susceptibility.

Peptilogicspeptilogics.comin𝕏

Peptilogics is a clinical-stage biotechnology company developing engineered peptide therapeutics, led by zaloganan (PLG0206), an anti-biofilm treatment for medical device-related infections.

BiotechHealthtechMedical DevicesPittsburg, US

Jonathan Steckbeck(Executive Officer, Director)

BoardStephan Dietrich(Director)

Telumtherapeuticstelumtherapeutics.comin𝕏

Telum Therapeutics is a drug discovery biotechnology company that uses synthetic biology and AI to engineer phage lytic enzymes (enzybiotics) as alternatives to traditional antibiotics.

AI & Machine LearningBiotechHealthtechNoΓ‘in, ES

Tennorxtennorx.com
Trellis BioscienceJan 2026

BiotechRedwood City, US

Larry Kauvar(Chief Science Officer)Stefan Ryser(President and Chief Executive Officer)Geoff Dillon(Chief Business Officer)Elisabeth Whitney(Chief Operating Officer)Nora Mende(Chief Financial Officer)

PartnerJunjun GaoΒ· ledHenry SkinnerΒ· quoted

Trellisbiotrellisbio.comin
Utility Therapeuticsacquired by Alembic Pharmaceuticals

Obtained U.S.

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.